DNTH

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Dianthus Therapeutics Inc.

NASDAQ | DNTH

35.03

USD

$0.00

(

0.00%

)

At Close (As of Oct 21, 2025)

$1.43B

Market Cap

-

P/E Ratio

-3.27

EPS

$40.15

52 Week High

$13.37

52 Week Low

HEALTHCARE

Sector

DNTH Chart

Recent Chart
Price Action

DNTH Technicals

Tags:

DNTH Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $6.2M
Total Revenue $6.2M
Cost Of Revenue $412K
Costof Goods And Services Sold $412K
Operating Income -$102M
Selling General And Administrative $25M
Research And Development $83M
Operating Expenses $108M
Investment Income Net -
Net Interest Income $17M
Interest Income $17M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $412K
Income Before Tax -$85M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$85M
Comprehensive Income Net Of Tax -
Ebit -$102M
Ebitda -$101M
Net Income -$85M

Revenue & Profitability

Earnings Performance

DNTH Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $374M
Total Current Assets $281M
Cash And Cash Equivalents At Carrying Value $23M
Cash And Short Term Investments $23M
Inventory -
Current Net Receivables $807K
Total Non Current Assets $93M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $82M
Short Term Investments $252M
Other Current Assets $4.9M
Other Non Current Assets -
Total Liabilities $22M
Total Current Liabilities $18M
Current Accounts Payable $4.6M
Deferred Revenue -
Current Debt -
Short Term Debt $320K
Total Non Current Liabilities $3.1M
Capital Lease Obligations $1.5M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.5M
Other Current Liabilities $13M
Other Non Current Liabilities -
Total Shareholder Equity $352M
Treasury Stock -
Retained Earnings -$174M
Common Stock $31K
Common Stock Shares Outstanding $33M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$78M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $412K
Capital Expenditures $105K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$287M
Cashflow From Financing $256M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$85M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $6.2M
Total Revenue $6.2M
Cost Of Revenue $412K
Costof Goods And Services Sold $412K
Operating Income -$102M
Selling General And Administrative $25M
Research And Development $83M
Operating Expenses $108M
Investment Income Net -
Net Interest Income $17M
Interest Income $17M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $412K
Income Before Tax -$85M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$85M
Comprehensive Income Net Of Tax -
Ebit -$102M
Ebitda -$101M
Net Income -$85M

DNTH News

DNTH Profile

Dianthus Therapeutics Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company based in New York dedicated to developing novel monoclonal antibody therapies for severe autoimmune and inflammatory diseases. The firm boasts a strong pipeline aimed at addressing significant unmet medical needs through its proprietary drug development programs. By advancing innovative solutions and progressing through critical clinical trials, Dianthus is positioning itself at the forefront of precision medicine, making it an attractive opportunity for institutional investors interested in pioneering advances within the biopharmaceutical sector.

BYND
+146.25%
$3.62
VHAI
0.00%
$0.00
YDKG
+27.99%
$0.05
YYAI
-19.18%
$0.08
F
+4.75%
$12.56
VSEE
+93.56%
$0.94
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
RANI
+26.66%
$2.85
NVDA
-0.81%
$181.16
GDXD
+28.69%
$0.86
AIRE
+61.36%
$0.72
BURU
-14.84%
$0.28
BITF
-9.83%
$4.49
PLUG
-8.23%
$3.12
ADAP
-17.62%
$0.04
T
-0.19%
$26.05
RGTI
-7.64%
$40.00
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
DNN
-7.16%
$2.72
BTG
-9.12%
$5.18
INTC
+0.05%
$38.11
WBD
+10.97%
$20.32
BOF
+33.65%
$2.80
JOBY
-7.63%
$16.10
CLF
-17.24%
$13.39
AXDX
-61.36%
$0.03
DVLT
+4.54%
$2.52
IBIO
+24.30%
$1.11
RIG
+0.60%
$3.31
GSIT
-16.26%
$10.86
TLRY
-5.73%
$1.48
NVTS
-12.10%
$15.03
RXRX
-8.53%
$6.11
ETHD
-0.80%
$3.72
SOFI
+0.24%
$28.75
ABEV
-2.20%
$2.22
TSLA
-1.07%
$442.60
RF
+1.24%
$24.36
AMZN
+2.56%
$222.03
EOSE
+8.59%
$16.30
GRAB
-1.23%
$5.60
AMD
-1.05%
$238.03
AAPL
+0.20%
$262.77
GOOGL
-2.37%
$250.46
QUBT
-7.40%
$16.00
ACHR
-4.75%
$11.41
LAES
-5.86%
$6.10
IONZ
+1.48%
$4.11
GM
+14.86%
$66.62
RR
+1.25%
$5.63
SOUN
-4.35%
$18.23
BTBT
-8.29%
$3.87
VALE
-1.14%
$11.27
BBD
-2.36%
$3.30
PFE
+0.64%
$24.85
QBTS
-6.42%
$32.19
MARA
-3.18%
$20.07
IREN
-6.79%
$55.19
HAL
+11.58%
$25.24
RMBL
+60.50%
$3.21
DCGO
+24.16%
$1.49
CJET
-20.45%
$0.08
AAL
+1.47%
$12.35
DFLI
-3.96%
$1.21
ADD
-25.47%
$0.05
GPUS
-7.57%
$0.36
CLSK
-7.99%
$18.77
NOK
-2.27%
$5.58
NIO
-3.68%
$6.80
SRM
+53.27%
$10.30
CIFR
-9.21%
$18.07
BMNR
-3.62%
$51.85
AMC
+4.33%
$2.89
KO
+4.06%
$71.22
PBR
-1.11%
$11.56
SNAP
+1.55%
$7.85
ONDS
-7.46%
$7.19
SMR
-13.20%
$38.36
VZ
-1.22%
$40.29
HBAN
+0.63%
$15.94
HIMS
-3.89%
$49.36
CUTR
-10.19%
$0.09
SMCI
-0.39%
$54.82
GGB
-1.17%
$3.37
WLGS
-5.57%
$0.04
PM
-3.83%
$152.00
RIVN
+0.91%
$13.20
GOOG
-2.20%
$251.34
PLTR
-0.04%
$181.51
BAC
-0.99%
$51.52
APLD
-9.35%
$32.54
EPWK
-8.71%
$0.07
RGTZ
+15.11%
$15.61
ETWO
0.00%
$3.30
BULL
-2.96%
$11.14
MSN
+59.31%
$0.76
IONQ
-0.73%
$59.50
AG
-11.21%
$12.75
BYND
+146.25%
$3.62
VHAI
0.00%
$0.00
YDKG
+27.99%
$0.05
YYAI
-19.18%
$0.08
F
+4.75%
$12.56
VSEE
+93.56%
$0.94
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
RANI
+26.66%
$2.85
NVDA
-0.81%
$181.16
GDXD
+28.69%
$0.86
AIRE
+61.36%
$0.72
BURU
-14.84%
$0.28
BITF
-9.83%
$4.49
PLUG
-8.23%
$3.12
ADAP
-17.62%
$0.04
T
-0.19%
$26.05
RGTI
-7.64%
$40.00
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
DNN
-7.16%
$2.72
BTG
-9.12%
$5.18
INTC
+0.05%
$38.11
WBD
+10.97%
$20.32
BOF
+33.65%
$2.80
JOBY
-7.63%
$16.10
CLF
-17.24%
$13.39
AXDX
-61.36%
$0.03
DVLT
+4.54%
$2.52
IBIO
+24.30%
$1.11
RIG
+0.60%
$3.31
GSIT
-16.26%
$10.86
TLRY
-5.73%
$1.48
NVTS
-12.10%
$15.03
RXRX
-8.53%
$6.11
ETHD
-0.80%
$3.72
SOFI
+0.24%
$28.75
ABEV
-2.20%
$2.22
TSLA
-1.07%
$442.60
RF
+1.24%
$24.36
AMZN
+2.56%
$222.03
EOSE
+8.59%
$16.30
GRAB
-1.23%
$5.60
AMD
-1.05%
$238.03
AAPL
+0.20%
$262.77
GOOGL
-2.37%
$250.46
QUBT
-7.40%
$16.00
ACHR
-4.75%
$11.41
LAES
-5.86%
$6.10
IONZ
+1.48%
$4.11
GM
+14.86%
$66.62
RR
+1.25%
$5.63
SOUN
-4.35%
$18.23
BTBT
-8.29%
$3.87
VALE
-1.14%
$11.27
BBD
-2.36%
$3.30
PFE
+0.64%
$24.85
QBTS
-6.42%
$32.19
MARA
-3.18%
$20.07
IREN
-6.79%
$55.19
HAL
+11.58%
$25.24
RMBL
+60.50%
$3.21
DCGO
+24.16%
$1.49
CJET
-20.45%
$0.08
AAL
+1.47%
$12.35
DFLI
-3.96%
$1.21
ADD
-25.47%
$0.05
GPUS
-7.57%
$0.36
CLSK
-7.99%
$18.77
NOK
-2.27%
$5.58
NIO
-3.68%
$6.80
SRM
+53.27%
$10.30
CIFR
-9.21%
$18.07
BMNR
-3.62%
$51.85
AMC
+4.33%
$2.89
KO
+4.06%
$71.22
PBR
-1.11%
$11.56
SNAP
+1.55%
$7.85
ONDS
-7.46%
$7.19
SMR
-13.20%
$38.36
VZ
-1.22%
$40.29
HBAN
+0.63%
$15.94
HIMS
-3.89%
$49.36
CUTR
-10.19%
$0.09
SMCI
-0.39%
$54.82
GGB
-1.17%
$3.37
WLGS
-5.57%
$0.04
PM
-3.83%
$152.00
RIVN
+0.91%
$13.20
GOOG
-2.20%
$251.34
PLTR
-0.04%
$181.51
BAC
-0.99%
$51.52
APLD
-9.35%
$32.54
EPWK
-8.71%
$0.07
RGTZ
+15.11%
$15.61
ETWO
0.00%
$3.30
BULL
-2.96%
$11.14
MSN
+59.31%
$0.76
IONQ
-0.73%
$59.50
AG
-11.21%
$12.75
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.